Press Release
On June 17th, 2022, Global Regulatory Partner Inc. through its subsidiary in Mexico submitted to the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the health authority in Mexico, seeking the approval of the freeze-dried version of smallpox vaccine.
The vaccine is indicated for active immunization against smallpox, monkeypox, and related orthopoxvirus infection and disease in adults 18 years of age and older who are considered to be at high risk of exposure. The vaccine can be used for both primary vaccination and revaccination.
On September 12th, 2024, Global Regulatory Partners Mexico LLC,recevied Marketing Authorization Approval from Mexico’s COFEPRIS.
About Global Regulatory Partners Group
Global Regulatory Partners, Inc (GRP) is a global provider of tailored clinical development, regulatory affairs, quality and pharmacovigilance services for pharma, biotech, medical devices and cosmetic industries worldwide.
Global Regulatory Partners. Inc, has now over 500 employees, 6 affiliates in 6 countries (USA, Brazil, Mexico, Japan, China and South Korea) and more than 500 satisfied clients worldwide.
In China, GRP-China has offices in three locations, Shanghai, Beijing and Hainan, and has local teams of Regulatory Affairs, Clinical Development ,Quality and Pharmacovigilance professionals, who support the clinical development and products’ registration of many pharmaceutical and medical device companies in Hainan pilot zone and in China Mainland as well.